DE69731756T2 - Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung - Google Patents

Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung Download PDF

Info

Publication number
DE69731756T2
DE69731756T2 DE69731756T DE69731756T DE69731756T2 DE 69731756 T2 DE69731756 T2 DE 69731756T2 DE 69731756 T DE69731756 T DE 69731756T DE 69731756 T DE69731756 T DE 69731756T DE 69731756 T2 DE69731756 T2 DE 69731756T2
Authority
DE
Germany
Prior art keywords
melanoma
antigens
melanoma cell
cells
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69731756T
Other languages
German (de)
English (en)
Other versions
DE69731756D1 (de
Inventor
M. Drew PARDOLL
M. Elizabeth JAFFEE
Adam Adler
L. Suzanne TOPALIAN
A. Steven ROSENBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
United States Department of Health and Human Services
Original Assignee
Johns Hopkins University
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, United States Department of Health and Human Services filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE69731756D1 publication Critical patent/DE69731756D1/de
Publication of DE69731756T2 publication Critical patent/DE69731756T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69731756T 1996-08-16 1997-08-04 Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung Expired - Lifetime DE69731756T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2409896P 1996-08-16 1996-08-16
US24098P 1996-08-16
PCT/US1997/012868 WO1998006746A2 (en) 1996-08-16 1997-08-04 Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same

Publications (2)

Publication Number Publication Date
DE69731756D1 DE69731756D1 (de) 2004-12-30
DE69731756T2 true DE69731756T2 (de) 2005-12-15

Family

ID=21818860

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69731756T Expired - Lifetime DE69731756T2 (de) 1996-08-16 1997-08-04 Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung

Country Status (8)

Country Link
US (1) US6187306B1 (cg-RX-API-DMAC10.html)
EP (1) EP0929318B1 (cg-RX-API-DMAC10.html)
JP (5) JP2001517206A (cg-RX-API-DMAC10.html)
AT (1) ATE283069T1 (cg-RX-API-DMAC10.html)
AU (1) AU3889997A (cg-RX-API-DMAC10.html)
CA (1) CA2263503C (cg-RX-API-DMAC10.html)
DE (1) DE69731756T2 (cg-RX-API-DMAC10.html)
WO (1) WO1998006746A2 (cg-RX-API-DMAC10.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1069917A4 (en) * 1998-03-20 2005-02-09 Genzyme Corp NEW COMPLEMENTARY PAIRS OF RECEPTORS / LIGANDS AND ADOPTIVE IMMUNOTHERAPY USING THE SAME
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
DE19905501B4 (de) * 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
AU2001253898A1 (en) 2000-06-22 2002-01-02 Aventis Pasteur Limited Continuous adherent melanocyte cell line
AU2003285863A1 (en) 2002-10-09 2004-05-04 Central Iowa Health System Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
GB2395270B (en) * 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
SI1889059T1 (sl) 2005-05-27 2009-12-31 Oncimmune Ltd Izboljšani imunotestni postopek
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
CN101632020B (zh) 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
EP2492300B1 (en) * 2009-10-23 2018-10-03 Dow Corning Toray Co., Ltd. Novel organopolysiloxane copolymer
EP4339287A3 (en) 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Modified cells and methods of therapy
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
KR20240024328A (ko) 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
CN111511375A (zh) 2017-06-30 2020-08-07 因提玛生物科学公司 用于基因治疗的腺相关病毒载体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595653A (en) 1981-06-09 1986-06-17 Lee Biomolecular Research Laboratories, Inc. Process for assaying cellular immunity
US5045320A (en) 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE69114299T3 (de) 1990-09-14 2005-09-15 The Johns Hopkins University Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems.
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
ATE230615T1 (de) * 1991-10-04 2003-01-15 Whitehead Biomedical Inst Regulierung der systemischen immunantworten mittels zytokinen und antigenen
ES2224113T5 (es) * 1994-02-16 2009-05-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Polipeptido antigenico asociado al melanoma, epitopos del mismo y vacunas contra melanoma.
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer

Also Published As

Publication number Publication date
JP2008044969A (ja) 2008-02-28
JP2014012738A (ja) 2014-01-23
JP2016106137A (ja) 2016-06-16
AU3889997A (en) 1998-03-06
DE69731756D1 (de) 2004-12-30
WO1998006746A3 (en) 1998-05-07
US6187306B1 (en) 2001-02-13
EP0929318A2 (en) 1999-07-21
CA2263503C (en) 2012-04-10
EP0929318B1 (en) 2004-11-24
JP2001517206A (ja) 2001-10-02
ATE283069T1 (de) 2004-12-15
CA2263503A1 (en) 1998-02-19
WO1998006746A2 (en) 1998-02-19
JP2012001548A (ja) 2012-01-05

Similar Documents

Publication Publication Date Title
DE69916581T2 (de) Eine universelle immunmodulatorische cytokin-expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen
CA2263503C (en) Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same
DE69718029T2 (de) Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6350445B1 (en) Method of treating cancer with a tumor cell line having modified cytokine expression
DE69834494T2 (de) Vorrichtung zur induktion einer ctl-antwort
DE69230506T2 (de) Lymphokine gentherapie bei krebs in kombination mit tumorantigenen
DE69114299T2 (de) Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems.
DE69839273T2 (de) Krebsimmuntherapie mit semi-allogenen zellen
DE69505391T2 (de) Implantierte vorrichtung mit tumorzellen zur behandlung von krebs
US5935568A (en) Gene therapy for effector cell regulation
EP1699480B1 (de) Allogenes tumortherapeutikum
DE60128070T2 (de) Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors
DE69627527T2 (de) Allogene parakrine cytokine tumor impfstoffe
DE69332921T2 (de) Hemmung des Tumorzellwachstums durch Verabreichung von B7-transfizierten Zellen
DE69232890T2 (de) Regulierung der systemischen immunantworten mittels zytokinen und antigenen
KR20010021706A (ko) Mhc 클래스 ⅱ 리간드의 예방접종을 위한 항항원체로의이용과 lag-3의 암 치료에의 이용
DE69634750T2 (de) DENDRITENZELLEN/TUMORZELLEN Hybirde ZUR INDUKTION EINER ANTI-TUMOR ANTWORT
JPH10505339A (ja) 腫瘍疾患の治療のための生ワクチン
Yei et al. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine
DE69331574T2 (de) Thymus-stammendes, immunverstärkendes agens zur therapeutischen verwendung in einem wirt mit einem angegriffenen immunsystem
WO2003072789A2 (de) Mikroorganismen als träger von nukleotidsequenzen kodierend für zellantigene zur behandlung von tumoren
DE60130634T2 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
WO2003045428A2 (de) Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung
DE60223232T2 (de) Mucinpeptid mit immunstärkenden eigenschaften
DE69731950T2 (de) Tumorvakzinierung mittels Verwendung autologer oder HLA-verwandter Antigen präsentierender Zellen (APC), die mit einem Tumorantigen sowie einem eine Immunantwort hervorrufenden Fremdantigen transduziert sind

Legal Events

Date Code Title Description
8364 No opposition during term of opposition